 Newly discovered biomarkers could provide physicians with information that will aid in the diagnosis and treatment of disease. The big question for investors is whether, in light of the recent Supreme Court ruling Mayo Collaborative Services Inc. v. Prometheus Laboratories, companies will be able to profit from that innovation.
|
|
Read more...
|
 Below is a look at some of the headlines for companies that made news in the healthcare sector on May 15, 2012.
|
|
Read more...
|
 Goldman Sachs upgrades Incyte (NASDAQ: INCY) from Neutral to Buy with a price target of $29 (up from $21), suggesting a 26% premium from today's prices as the drug discovery company focused on developing proprietary small molecule drugs becomes the latest M&A target.
|
|
Read more...
|
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 14, 2012.
|
|
Read more...
|
 In an exclusive interview with Liz Cermak, Executive Vice President and Chief Commercial Officer of POZN, we discuss the implications of a European licensing deal for their migrane drug MT 400.
|
|
Read more...
|
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 11, 2012.
|
|
Read more...
|
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 10, 2012.
|
|
Read more...
|
